Purple Biotech (PPBT) Competitors $0.58 +0.01 (+1.30%) Closing price 03:53 PM EasternExtended Trading$0.58 +0.00 (+0.34%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT vs. RNTX, SONN, DARE, ENLV, CVKD, PASG, LPTX, PMN, LNAI, and CASIShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include Rein Therapeutics (RNTX), Sonnet BioTherapeutics (SONN), Dare Bioscience (DARE), Enlivex Therapeutics (ENLV), Cadrenal Therapeutics (CVKD), Passage Bio (PASG), Leap Therapeutics (LPTX), Promis Neurosciences (PMN), Lunai Bioworks (LNAI), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. Its Competitors Rein Therapeutics Sonnet BioTherapeutics Dare Bioscience Enlivex Therapeutics Cadrenal Therapeutics Passage Bio Leap Therapeutics Promis Neurosciences Lunai Bioworks CASI Pharmaceuticals Rein Therapeutics (NASDAQ:RNTX) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Do institutionals and insiders hold more shares of RNTX or PPBT? 90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings & valuation, RNTX or PPBT? Purple Biotech is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRein TherapeuticsN/AN/A-$62.88M-$2.69-0.45Purple BiotechN/AN/A-$7.24M-$0.42-1.39 Does the media prefer RNTX or PPBT? In the previous week, Purple Biotech had 3 more articles in the media than Rein Therapeutics. MarketBeat recorded 3 mentions for Purple Biotech and 0 mentions for Rein Therapeutics. Purple Biotech's average media sentiment score of 0.33 beat Rein Therapeutics' score of 0.00 indicating that Purple Biotech is being referred to more favorably in the news media. Company Overall Sentiment Rein Therapeutics Neutral Purple Biotech Neutral Which has more volatility and risk, RNTX or PPBT? Rein Therapeutics has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Do analysts recommend RNTX or PPBT? Rein Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 719.67%. Purple Biotech has a consensus target price of $33.00, suggesting a potential upside of 5,560.38%. Given Purple Biotech's higher possible upside, analysts plainly believe Purple Biotech is more favorable than Rein Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Purple Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is RNTX or PPBT more profitable? Purple Biotech's return on equity of -14.00% beat Rein Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rein TherapeuticsN/A -141.11% -33.83% Purple Biotech N/A -14.00%-12.52% SummaryPurple Biotech beats Rein Therapeutics on 7 of the 11 factors compared between the two stocks. Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.49M$3.40B$6.21B$10.54BDividend YieldN/A2.27%5.74%4.88%P/E Ratio-1.3923.0629.1327.15Price / SalesN/A436.69553.81164.89Price / CashN/A46.4037.3861.65Price / Book0.0510.4512.306.46Net Income-$7.24M-$52.53M$3.33B$276.63M7 Day Performance-9.22%-1.46%-1.46%-2.60%1 Month Performance2.77%9.70%5.03%0.33%1 Year Performance-87.04%11.69%61.45%30.66% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.3183 of 5 stars$0.58+1.3%$33.00+5,560.4%-87.2%$7.49MN/A-1.3920News CoverageRNTXRein Therapeutics2.6232 of 5 stars$1.32+1.5%$10.00+657.6%N/A$30.30MN/A-0.499SONNSonnet BioTherapeutics1.7068 of 5 stars$4.37-0.9%$20.00+357.7%-31.9%$30.11M$20K0.0010Gap DownDAREDare Bioscience1.8225 of 5 stars$2.12flat$10.00+371.7%-41.5%$28.58M$10K-0.9930Positive NewsENLVEnlivex Therapeutics2.5237 of 5 stars$1.10-4.3%$10.00+809.1%-28.4%$27.94MN/A-1.9070Gap DownCVKDCadrenal Therapeutics2.8963 of 5 stars$13.99+2.7%$32.00+128.7%-13.4%$27.88MN/A-1.584Gap UpPASGPassage Bio3.0982 of 5 stars$8.69+2.6%$75.67+770.7%-26.2%$26.93MN/A-0.48130News CoverageGap DownLPTXLeap Therapeutics2.7749 of 5 stars$0.60-5.5%$3.38+459.6%-83.7%$26.46MN/A-0.3840Short Interest ↓PMNPromis Neurosciences3.7442 of 5 stars$0.48-2.0%$4.33+802.8%-53.7%$26.37MN/A-2.295News CoveragePositive NewsShort Interest ↓LNAILunai BioworksN/A$1.16+2.7%N/AN/A$26.19MN/A-0.1520Gap DownCASICASI Pharmaceuticals3.5814 of 5 stars$1.89-4.5%$4.00+111.6%-68.4%$24.35M$28.54M-0.65180 Related Companies and Tools Related Companies Rein Therapeutics Competitors Sonnet BioTherapeutics Competitors Dare Bioscience Competitors Enlivex Therapeutics Competitors Cadrenal Therapeutics Competitors Passage Bio Competitors Leap Therapeutics Competitors Promis Neurosciences Competitors Lunai Bioworks Competitors CASI Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PPBT) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
